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ABSTRACT: Chemogenetic tools such as designer receptors
exclusively activated by designer drugs (DREADDs) are rou-
tinely used to modulate neuronal and non-neuronal signaling
and activity in a relatively noninvasive manner. The ﬁrst
generation of DREADDs were templated from the human
muscarinic acetylcholine receptor family and are relatively insen-
sitive to the endogenous agonist acetylcholine but instead are
activated by clozapine-N-oxide (CNO). Despite the undisputed
success of CNO as an activator of muscarinic DREADDs, it has
been known for some time that CNO is subject to a low rate of
metabolic conversion to clozapine, raising the need for alterna-
tive chemical actuators of muscarinic-based DREADDs. Here
we show that DREADD agonist 21 (C21) (11-(1-piperazinyl)-
5H-dibenzo[b,e][1,4]diazepine) is a potent and selective agonist at both excitatory (hM3Dq) and inhibitory (hM4Di) DREADDs
and has excellent bioavailability, pharmacokinetic properties, and brain penetrability. We also show that C21-induced activation
of hM3Dq and hM4Di in vivo can modulate bidirectional feeding in deﬁned circuits in mice. These results indicate that C21
represents an alternative to CNO for in vivo studies where metabolic conversion of CNO to clozapine is a concern.
KEYWORDS: clozapine-N-oxide, clozapine, DREADD, designer receptors exclusively activated by designer drugs,
muscarinic acetylcholine receptors
Over the past decade, several technologies have been devel-oped to provide chemogenetic modulation of neuronal
and non-neuronal signaling. These include engineered ion chan-
nels,1,2 kinases,3 and G protein coupled receptors (GPCRs).4−6
Of these, it is the GPCR-based designer receptors exclusively
activated by designer drugs (DREADDs)6 that are most fre-
quently used among neuroscientists and other biologists.
Currently there are several classes of DREADDs including
(1) those based on human muscarinic acetylcholine receptors
(mAChRs) which are coupled to Gαq (hM1Dq and hM3Dq)
and activate neuronal signaling and ﬁring,6,7 (2) those which
are coupled to Gαi (hM4Di) and inhibit adenylate cyclase and
attenuate neuronal activity and neurotransmitter release,6 and
(3) those which preferentially couple to Gαs (GsD),8 one
which preferentially couples to arrestin,9 and one which
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activates Gαq but is not coupled to arrestin translocation.10
Additional DREADDs based on k-opioid receptors (KORD)11
and the free fatty acid receptor type 2 (FFAR2)12 have also
been reported. Among these, the muscarinic based DREADDs
are the most commonly used and were designed to be
activated by clozapine’s pharmacologically inert metabolite
clozapine-N-oxide (CNO), although as originally reported
muscarinic DREADDs are also potently activated by cloza-
pine.6 These muscarinic DREADDs are relatively insensitive to
acetylcholine6,8 and hence can be used in vivo and in vitro to
aﬀord selective control of cellular signaling via peripheral or
local administration of CNO.7,8
It has long been appreciated that CNO can undergo meta-
bolic transformation to clozapine, with estimates ranging from
a few percent in rodents13 to approximately 10% in humans,
nonhuman primates (NHPs) and guinea pigs.14−16 For instance,
following systemic administration of 10 mg/kg CNO, cloza-
pine levels in cerebrospinal ﬂuid (CSF) have been reported
to reach 34 and 43 nM for the major clozapine metabolite,
N-desmethylclozapine (NDMC).16 Given that clozapine has
potent activity at more than 50 distinct molecular targets,17,18
while NDMC activates the M1 mAChR possibly through an
atypical mechanism,19−21 such CNO back-metabolism could
give rise to the activation of a spectrum of oﬀ-target responses.
Indeed, the concentrations of each CNO metabolite detected
in NHP CSF are suﬃcient to activate oﬀ-target CNS receptors
such as serotonin and dopamine receptors.16,22
Although the extensive literature using CNO as an eﬀective
actuator of muscarinic DREADDs (reviewed in refs 23 and 24)
provides a high degree of conﬁdence in the use of CNO:
DREADD pairing and that the measurements of back
metabolism of CNO could be overestimated depending upon
the analytic technique used,25 while the route of CNO admin-
istration can also aﬀect the levels of clozapine detected post-
administration.16 It is nonetheless conceivable that even a low
rate of conversion could lead to pharmacologically relevant
actions of clozapine upon CNO administration.26 Indeed,
although the vast majority of published studies have not
reported any measurable behavioral, cardiovascular, metabolic,
or endocrinologic action of low-dose CNO in mice and rats,26
there have been a small number of reports of actions of CNO
in non-DREADD animals.27,28 Given that both clozapine and
NDMC can themselves activate both wildtype and DREADD
mAChRs19−21 and that low brain permeability for CNO has
been reported,29 it is diﬃcult to determine whether the activa-
tion of mAChR DREADDs following CNO administration
arises from CNO itself or whether this arises as a result of
CNO metabolism. If CNS DREADDs are indeed activated
by these metabolites, then it may be diﬃcult to control the
concentration of active drug that reaches the target site. For
certain studies, therefore, where CNO back metabolism is con-
sidered to be a concern, there is a need for non-CNO chemo-
genetic actuators for the muscarinic DREADDs.
DREADD Agonist 21 (C21) was recently reported as a non-
CNO chemogenetic actuator for muscarinic hM3Dq.30 Mean-
while, perlapine, an approved hypnotic drug, was identiﬁed as a
potential DREADD agonist during a broad library screen of
existing compounds and exhibited both binding and Ca2+
mobilization at the hM3Dq receptor.30 However, both com-
pounds have only thus far been assessed at hM3Dq. Given that
the M1 and M4 subunits are implicated in a broad range of
neurodegenerative diseases and schizophrenia,31−33 the
DREADD receptors are particularly useful in dissecting signaling
pathways for these subtypes. We therefore carried out a
comprehensive in vitro and in vivo characterization of C21 and
perlapine to assess their potential for use as an alternative
to CNO. We ﬁnd that C21 has (1) few oﬀ-target actions,
(2) favorable pharmacokinetic properties, (3) excellent brain
penetration, and (4) potently activates the hM4Di inhibitory
and hM3Dq excitatory DREADDs in vivo. Thus, C21
represents an alternative chemogenetic actuator for studies
with muscarinic-based DREADDs.
■ RESULTS
C21 Potently Activates hM1Dq, hM3Dq, and hM4Di
in Vitro. We have previously reported that both C21 and
perlapine potently activated hM3Dq in Chinese hamster ovary
(CHO) cells transfected cells in vitro,30 and their data are
conﬁrmed here with C21 and perlapine stimulating calcium
mobilization at hM3Dq with a pEC50 of 8.48 ± 0.05 and 8.08 ±
0.05, respectively (Figure S1). We extended this analysis of C21
and perlapine to other muscarinic based DREADDs, namely,
hM1Dq and hM4Dq. Using radioligand competition binding,
we show that all three muscarinic DREADD ligands, CNO,
C21, and perlapine, interact with the wildtype hM1 and hM4
receptors with relatively low aﬃnity (Figure 1A,B; Table 1).
Both C21 and CNO had a >10-fold higher aﬃnity at the
hM1Dq and hM4Di, whereas acetylcholine showed a >10-fold
reduction in binding aﬃnity at both muscarinic DREADD
receptors (Figure 1C,D; Table 1). Unlike the other muscarinic
DREADD ligands, perlapine showed only a small increase in
binding aﬃnity at hM1Dq and hM4Di compared to that of
wildtype receptors (Figure 1A−D; Table 1).
In these experiments, the expression of the muscarinic
receptors in transfected CHO cells were very similar between
cell types (hM1 = 2 580 166 ± 185 544 sites/cell, hM1Dq =
337 998 ± 130 471, hM4 = 351 322 ± 88 571, hM4Di =
129 804 ± 15 988). Despite exhibiting modest binding aﬃn-
ities for wildtype hM1 receptors (Figure 1A), CNO, C21, and
perlapine displayed no agonist activity in IP1 or pERK1/2
assays at this receptor (Figure 2A,B; Table 1). In contrast, all
three muscarinic DREADD ligands were potent agonists in
IP1 and pERK1/2 assays of hM1Dq activation (Figure 2C,D;
Table 1). C21, perlapine, and CNO were also evaluated as
agonists of hM4Di in assays that measure inhibition of
isoproterenol-stimulated cAMP production and pERK1/2
(Figure 3A, B). At both of these responses, all three DREADD
ligands had submicromolar potency at hM4Di (Figure 3A,B),
whereas they had weak/no activity at the wildtype hM4 recep-
tor (Figure 3C,D; Table 1).
Pharmacological Proﬁle of C21. To assess the utility of
C21 as a potential chemogenetic actuators suitable for in vivo
studies, we performed a comprehensive evaluation of potential
oﬀ-target activities at a large number of GPCRs via the resources
of the National Institute of Mental Health Psychoactive Drug
Screening Program (NIMH-PDSP). Radioligand binding studies
indicated that C21 interacted with a wide range of GPCRs
(Figure 4; Table S1).
To further evaluate C21 for potential oﬀ-target activity, a
near genome-wide screen of C21 agonist activity at druggable
nonolfactory GPCR-ome was conducted as previously
described.37 At a single concentration (5 μM), C21 showed
agonist activity only at M4-, D2-, and H4-histamine receptors
(Figure 5; Table S2). However, conﬁrmatory follow-up
concentration−response studies revealed minimal activity of
C21 at D1-, D2-, D3-, and H4- receptors (Figure 6A−D).
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The reason for the discrepancy between the high throughput
results and the more detailed analysis is not clear, but overall
our data suggests that if used in vivo C21 would likely show
minimal oﬀ-target agonist activity at the tested 318 nonolfactory
GPCRs.
Potential Antagonist Activity of C21. Given the binding
data presented above indicating that C21 showed weak binding
aﬃnity to wildtype hM1 and hM4 receptors (pKi = 5.97 and
5.44 respectively; see Table 1) as well as weak to moderate bind-
ing to a number of other nonolfactory GPCRs (see; Figure 4
and Table S1), C21 might display antagonist activity at these
receptors. We therefore conducted analysis of C21 in antag-
onist mode at a representative group of GPCRs. At hM1 and
hM4, C21 shifted the acetylcholine concentration response
curve in pERK assays to the right indicating weak functional
antagonism at these receptors (Figure S2a,b). We also observed
antagonism of C21 at human D1 receptors using a cAMP
assay and human D2 receptors using a Gi-dissociation assay
(Figure S3a,b). In the case of human H4 histamine receptors
which bound C21 with very low aﬃnity (pKi < 5, Table S1) no
antagonism was observed in a Gi-dissociation assay (Figure S3c).
These data indicated that although C21 was a highly selec-
tive and potent agonist for muscarinic DREADDs (pEC50 for
hM1Dq = 8.91 and that for hM4Di = 7.77) the fact that C21
showed weak to moderate binding aﬃnity at a range of
wildtype GPCRs (including wildtype muscarinic receptors) it
is possible that this might translate to functional antagonism
in vivo. As such, care needs to be taken with in vivo dosing of C21
to ensure that the free concentration of compound remains in a
range that activates muscarinic DREADDs but is suﬃciently
low to avoid antagonism at wildtype GPCRs.
Pharmacokinetic Properties of C21 and Perlapine.
The in vitro analysis of C21 encouraged further evaluation of
this compound as an alternative in vivo chemogenetic actuator
by analysis of the pharmacokinetic properties of C21 compared
to CNO and perlapine. Intraperitoneal administration of CNO
at 0.3, 1, and 1.5 mg/kg led to elevations in plasma levels of the
compound, but there was no evidence of CNO in the brain
(Figure 7A). Since CNO can be back-metabolized to clozapine,
the concentrations of clozapine following CNO administration
were also determined. Clozapine was present in both the plasma
and brain, at levels indicative of signiﬁcant back-metabolism of
CNO in these animals (Figure 7A). It is noteworthy that
clozapine in these brain samples displayed 95% protein binding.
In contrast to CNO, intraperitoneal (i.p.) administration of both
C21 and perlapine at 0.1, 1, and 10 mg/kg demonstrated mea-
surable brain and plasma levels of each compound 30 min after
administration with no evidence of metabolism to clozapine
(Figure 7B,C). A time course of C21 accumulation in the brain
and plasma following administration of 5 mg/kg demonstrated
that plasma levels peaked at 1150 ng/mL (4.12 μM), whereas
brain levels reached 579 ng/mL (2 μM) (Figure 7D). Despite
these relatively high concentrations, C21 displayed 95.1%
plasma protein binding (4.7% unbound) and 95% brain protein
bounding (4.9% unbound) (Figure 7E). Thus, the eﬀective free
concentrations of C21 at the peak measured in these studies
represent ∼54 nM in plasma and 28 nM brain. On the basis of
these pharmacokinetic considerations, we opted to evaluate
C21 in mice at doses as low as 0.3 mg/kg which were calcu-
lated to aﬀord a free brain concentration of C21 of ∼1.7 nM.
Additionally, we chose not to exceed doses of 3 mg/kg, which
would achieve a free concentration of ∼17 nM, to minimize
potential oﬀ-target actions.
C21 Activates Neuronal hM3Dq in Vitro and in Vivo.
The studies described above together with our previous work
using hM3Dq30 support the notion that C21 is a potential
alternative actuator of muscarinic-based DREADDs in vivo.
To test this notion further, we focused on hM3Dq, a musca-
rinic DREADD commonly used by neurobiologists to activate
neuronal circuitary. Our initial studies were performed with
lateral hypothalamic vGAT-expressing neurons virally induced
to express hM3Dq. In these preparations, C21 (1 μM) was seen
to cause depolarization in hM3Dq-expressing neurons but not in
control infected neurons (Figure 8A,B). As activation of these
neurons in vivo by peripheral CNO administration has been
previously demonstrated, we next tested a cohort of mice with
increasing doses of C21. As can be seen, C21 drives feeding in
Figure 1. Binding of muscarinic DREADD ligands to DREADDs and wildtype receptors. Displacement of [3H]-NMS by increasing concentrations
of ACh, CNO, C21, or perlapine at (A) hM1, (B) hM4, (C) hM1Dq, and (D) hM4Di. All experiments were performed using a Kd concentration of
[3H]-NMS. Data represents the mean ± SEM of at least three experiments performed in duplicate.
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a dose-dependent fashion (Figure 8C−E) with a maximal res-
ponse similar to 3 mg/kg CNO (Figure 8F).
Agouti-related peptide (AgRP) neurons, localized in the
arcuate nucleus (ARC), display appetite-state-dependent,
dynamic activity changes38−41 and are critical regulators of appe-
tite.42−45 Acute chemogenetic activation of ARCAgRP neurons
utilizing stimulatory Gq-coupled DREADDs and the ligand
CNO rapidly and robustly escalates feeding behavior in calo-
rically replete mice.42,46 Here, we assessed the capacity of C21
to activate hM3Dq expressed in ARCAgRP neurons and evoke
food intake in sated animals. We found that C21-mediated
stimulation of AgRP-hM3Dq-expressing ARCAgRP neurons
dose-dependently promoted food consumption at comparable
levels to CNO administered at the same concentrations
(Figure 9A−C). Importantly, neither C21 nor CNO aﬀected
feeding behavior in wildtype, (non-Cre-expressing) litter-
mate controls injected with AAV-DIO-hM3Dq-mCherry
(Figure 9D−F).
C21 Drives Behaviors Modulated by hM4Di in Vivo.
The paraventricular nucleus (PVH) is a key anatomical struc-
ture for the maintenance of energy balance and has recently
been identiﬁed as a downstream signaling site of ARCAgRP neu-
rons.38,47,48 Single-minded 1 (SIM1) is a transcription factor
necessary for proper development of the PVH. Conditional,
postnatal SIM1 knockout mice as well as animals devoid of
PVHSIM1-expressing neurons display hyperphagia-induced
obesity.49,50 Additionally, chemogenetic silencing of PVHSIM1
neurons promptly drives food consumption in otherwise sated
mice.47,51 Here, we examined the suﬃciency of C21 to activate
hM4Di expressed in PVHSIM1 neurons and facilitate food
intake in calorically replete mice. We found that C21-mediated
stimulation of hM4Di-expressing PVHSIM1 neurons substan-
tially enhanced food consumption at comparable levels to CNO
administered at the same concentrations (Figure 10 A,B). Nota-
bly, as observed in wildtype, neither C21 nor CNO ligand inﬂu-
enced food intake in a separate cohort of wildtype, (non-Cre-
expressing) littermate control mice injected with AAV-DIO-
hM4Di-mCherry (Figure 10C,D).
■ DISCUSSION
Muscarinic receptor based DREADDs activated by CNO have
proven powerful tools to determine signaling pathways that
underlie central and peripheral responses.23,24 The majority of
these previous in vivo studies have been conducted with CNO
doses that were suﬃcient to show a response only in the
DREADD expressing animals and not in control animals.
Under these carefully controlled conditions the responses
observed following CNO administration can only have been
derived from activation of DREADD receptors. Hence, pro-
vided rigorous experimental design is employed, using CNO as
an actuator of the muscarinic DREADDs has proven to be a
perfectly valid approach.
Despite the success of CNO:DREADD pairing the back
metabolism of CNO to clozapine as demonstrated in both
rodent and nonhuman primates13−15 have raised concerns that
clozapine and not CNO might be the activator of genetically
engineered DREADD receptors in animal studies.28 In support
of these concerns are the data presented here where we were
unable to detect CNO in the brain following intraperitoneal
administration of CNO; rather, clozapine was detected in the
brain and increased in a dose-dependent manner following
CNO administration. Importantly, the levels of clozapine
achieved following CNO administration was not suﬃcient toT
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induce oﬀ-target eﬀects in wildtype animals (for example on feed-
ing behavior) even at supra-maximal doses (e.g., 3 mg/kg).
Hence, in our hands, as seen in many other studies (e.g., refs 42,
52, and 53), eﬀects of CNO administration on behavior was
only evident in mice induced to express muscarinic DREADDs.
Thus, the levels of CNO back metabolism observed here were
not suﬃcient to mediate signiﬁcant changes for the observed
responses in animals not expressing muscarinic DREADDs.
To address the concerns regarding back-metabolism of
CNO, we set out to establish if novel DREADD ligands, based
on the CNO scaﬀold, might oﬀer an alternative actuator of
muscarinic DREADDs. Here we investigated two such ligands,
C21 and perlapine, which we have previously shown to act as
agonists at the Gq DREADD, hM3Dq,
30 and which we report
do not undergo back-metabolism to clozapine. While both
of these ligands interacted with the wildtype hM1 and hM4
receptors, they showed >10-fold higher aﬃnity for the
DREADD variants of these receptors and importantly act as
agonists at hM1Dq and hM4Di while lacking agonist activity at
wildtype receptors. Against a panel of nonolfactory GPCRs,
C21 and perlapine showed at least 10-fold lower aﬃnity for the
majority of GPCRs tested than seen for the muscarinic
DREADDs. There were however some exceptions, such as
members of the serotonin receptor family (e.g., 5HT2A, 5HT2C,
and 5HT7) as well as the dopamine D1 and histamine H1
receptors, where aﬃnities for both C21 and perlapine were
similar to, or greater than, that observed for the muscarinic
DREADDs. Despite these data demonstrating binding of C21
to some GPCR targets, activity assays conducted on a panel of
318 nonolfactory GPCRs, and subsequent conﬁrmatory
Figure 2. Signaling at hM1 and hM1Dq mediated by muscarinic DREADD ligands. Concentration response curves for ACh, CNO, C21, and
perlapine in (A) IP1 accumulation mediated by hM1, (B) ERK 1/2 activation mediated by hM1, (C) IP1 accumulation mediated by hM1Dq, and
(D) ERK 1/2 activation mediated by hM1Dq. Data represents the mean ± SEM of at least three experiments performed in duplicate.
Figure 3. Signaling at hM4 and hM4Di mediated by muscarinic DREADD ligands. Concentration response curves for ACh, CNO, C21, and
perlapine in (A) inhibition of isoproterenol elevated cAMP by hM4Di, (B) ERK 1/2 activation mediated by hM4Di, (C) inhibition of
isoproterenol elevated cAMP by hM4, and (D) ERK 1/2 activation mediated by hM4. Data represents the mean ± SEM of at least three
experiments performed in duplicate.
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studies, indicated that C21 was devoid of activity at the
receptors tested, including receptors of the dopamine, sero-
tonin, and histamine receptor families. Hence, C21 appeared
to be a highly selective muscarinic DREADD actuator with no
evidence of signiﬁcant oﬀ-target GPCR agonist activity.
There does however remain the possibility that C21 might
act as a functional antagonist at those GPCRs to which binding
was observed. We tested this possibility directly for a subset of
wildtype GPCRs and determined that at least in the case of the
wildtype hM1, hM4, hD1, and hD2 receptors that C21 did
indeed act as a weak antagonist. It is therefore important for
researchers using C21 in vivo to bear in mind that high doses of
C21 might lead to levels of free ligand that mediate GPCR
antagonism. In vivo experiments must therefore be conducted
with the appropriate controls where C21 is administered to
animals that do not express the muscarinic DREADDs. In this
way, oﬀ-target C21 behaviors/responses will be clearly iden-
tiﬁed. In the in vivo experiments conducted in our study, we
found that concentrations of C21 that resulted in changes in
feeding behavior in the muscarinic DREADD expressing ani-
mals had no oﬀ-target eﬀects in control animals where musca-
rinic DREADDs were not expressed (see discussion below).
The in vivo activity of C21 was tested by viral-induced expres-
sion of hM3Dq in LHvGAT or ARCAgRP neurons of the hypo-
thalamus which have previously been shown to induce feeding
on CNO administration.46,54 Employing this model, C21 admin-
istered at doses that gave no feeding response in animals expres-
sing wildtype hM3 produced a robust feeding response that
mimicked that seen with CNO. Similarly, silencing of SIM1
neurons in the paraventricular hypothalamus via activation of
virally transduced hM4Di has previously been associated with
an increase in feeding response.52 Here administration of C21
mimicked CNO activity by increasing feeding in this model.
Collectively, these in vivo studies support the notion that C21
represents an eﬀective alternative actuator for muscarinic
DREADDs.
Overall, we conclude that whereas CNO has proved to be an
eﬀective actuator of muscarinic DREADDs and, provided con-
trols are in place, will continue to be an excellent ligand tool,
concerns regarding potential oﬀ-target responses arising from
back-metabolism of CNO to clozapine might be overcome by
using C21 as an alternative selective agonist for muscarinic
DREADDs.
■ METHODS
Mouse Handling for Feeding Studies. Animal care pro-
cedures were approved at the National Institutes of Health as
well as UNC and the UK Home Oﬃce. Mice (10−12 week old
males) were singly housed for at least 2.5 weeks following sur-
gery and handled for 10 consecutive days before the assay to
reduce stress response. Feeding studies were performed in home
cages with ad libitum food access. Home cages were changed
every day during food intake measurements to eliminate residual
food crumbs in the bedding. CNO or C21 was administered at
Figure 4. Determination of C21 and perlapine binding aﬃnities at a
panel of GPCR drug targets. Binding aﬃnity (pKi) was determined at
indicated receptors and targets using radioligand binding assays with
membrane preparations and provided by NIMH PDSP. Results were
presented as mean ± SEM from a minimum of 3 independent assays,
each in triplicate. Indicated are those receptors where the pKi values
are less than 5. The raw data is presented in Table S1.
Figure 5. Assessment of oﬀ-target activity of C21 against 318
nonolfactory GPCR targets. Agonist activity of C21 at 318 nonolfactory
human GPCRs at a ﬁnal of 5 μM. Results were represented as fold of
basal in quadruplicate. Dopamine receptor DRD2 with 100 nM
Quinpirole served as an assay control (Control). The GPCRome
screening assay was carried out as outlined in the Methods section and
plotted using Prism. The raw data is presented in Table S2.
Figure 6. Assessment of activity of C21 at dopamine D1−D3
and histamine H4 receptors. Activation of cAMP signaling at
(A) dopamine D1 receptors stimulated with C21 and SKF81297,
(B) dopamine D2 receptors stimulated with C21 and quinpirole,
(C) dopamine D3 receptors stimulated with C21 and quinpirole, and
(D) histamine H4 receptors stimulated with C21 and histamine. Data
shown represents the mean ± SEM of at least three independent
experiments performed in duplicate.
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0.3, 1.0, or 3.0 mg per kg of body weight. Saline was delivered at
the same volume as CNO or C21 to maintain consistency in the
studies. Mice with “missed” viral injections, incomplete “hits”,
or expression outside the area of interest were excluded
from analysis after post hoc examination of mCherry
expression.
Feeding Studies in Sim1-Cre Mice. During the light
cycle, animals injected with AAV8-hSyn-DIO-hM4Di-mCherry
(Sim1-Cre, n = 6; WT, n = 6) were injected with either saline,
CNO, or C21 (i.p.) and food intake was measured 0.5, 1.0, 2.0,
and 3.0 h after injection. A full trial consisted of assessing food
intake from the study subjects after they received injections of
saline, CNO, and C21 over 3 days in a crossover design.
Feeding Studies in Agrp-ires-Cre Mice. During the light
cycle, animals injected with AAV8-hSyn-DIO-hM3Dq-
mCherry (Agrp-ires-Cre, n = 6; WT, n = 4) were injected with
either saline, CNO, or C21 (i.p.), and food intake was measured
0.5, 1.0, 2.0, and 3.0 h after injection. A full trial consisted of
assessing food intake from the study subjects after they received
injections of saline, CNO, and C21 over 3 days in a crossover
design.
Whole-Cell Radioligand Binding Assays. FlpIn CHO
cells stably expressing the hemaglutinine (HA)-tagged wildtype
human M1 or M4 (hM1 or M4 WT) mAChRs were plated at
the density of 20 000, and the human M1 DREADD (hM1Dq)
or M4 DREADD (hM4Di) mAChRs were plated at 50 000 cells
per well of 96-well white clear-bottomed Isoplates (PerkinElmer
Life Sciences, Boston, MA), and grown overnight.
Saturation binding assays were performed to estimate the
expression levels (Bmax) and equilibrium dissociation constant
of the radioligand (Kd). Cells were washed twice with
phosphate-buﬀered saline (PBS), and incubated with 0.03−
10 nM [3H]NMS in a ﬁnal volume of 100 μL of buﬀer (20 mM
HEPES, 100 mMNaCl, 10 mMMgCl2, pH 7.4) for 4 h at room
temperature. Atropine at the ﬁnal concentration of 100 μM
was used to determine nonspeciﬁc binding.
For equilibrium binding assays, cells were incubated with
increasing concentrations of the ligands or 100 μM atropine,
for nonspeciﬁc binding, in the presence of Kd concentration of
the radioligand for 4 h at room temperature. The assays were
terminated by rapid removal of the radioligand, and two
washes with 100 μL/well ice-cold 0.9% NaCl buﬀer. Radio-
activity was determined by addition of 100 μL/well MicroScint
scintillation liquid (PerkinElmer Life Sciences, Boston, MA)
and counted on a MicroBeta plate reader (PerkinElmer Life
Sciences, Boston, MA).
IP-One Accumulation Assays. FlpIn CHO-hM1 WT,
hM4 WT, hM1Dq, or hM4Di cells were seeded at the density
of 10 000 per well in 96-well transparent cell culture plates.
The following day, cells were preincubated for 1 h with IP1
stimulation buﬀer (1 mM CaCl2, 0.5 mM MgCl2, 4.2 mM KCl,
146 mM NaCl, 5.5 mM D-glucose, 10 mM HEPES, and 50 mM
LiCl, pH 7.4). Cells were then stimulated with ligands in IP1
stimulation buﬀer for 1 h at 37 °C, 5% CO2, and then lysed with
40 μL/well (for hM1 or M4 WT) or 25 μL/well (for hDi or
Dq) IP1 lysis buﬀer (50 mM HEPES pH 7.0, 15 mM KF, 1.5%
v/v Triton-X-100, 3% v/v FBS, 0.2% w/v BSA). IP1 levels were
measured by incubation of cell lysates with FRET reagents (the
cryptate-labeled anti-IP1 antibody and the d2-labeled IP1
analogue) for 1 h at 37 °C. The emission signals were measured
at 590 and 665 nm after excitation at 340 nm on an EnVision
plate reader (PerkinElmer Life Sciences, Boston, MA). Signals
were expressed as the FRET ratio F = (ﬂuorescence665nm/
ﬂuorescence590nm) × 10
4 and normalized to the maximal
response to ACh (for hM1 WT or hM4 WT) or CNO (for
hM1Dq or hM4Di).
ERK1/2 Phosphorylation (pERK1/2) Assays. FlpIn
CHO-hM1 WT, hM4 WT, hM1Dq, or hM4Di cells were at
seeded at 10 000 cells per well in 96-well transparent cell cul-
ture plates. The following day, cells were washed twice with
PBS and incubated in serum-free DMEM, supplemented with
8 mM HEPES for 6 h at 37 °C to reduce FBS-stimulated
Figure 7. Analysis of brain and plasma exposure for CNO, C21, and perlapine. (A) Unbound fraction of plasma and brain CNO and clozapine
levels following i.p. administration of various concentrations of CNO. (B) Unbound fraction of plasma and brain levels of perlapine following i.p.
administration of various concentrations of perlapine. (C) Unbound fraction of plasma and brain levels of C21 following i.p. administration
of various concentrations of C21. (D) Time course of C21 brain and plasma exposure following i.p. administration of C21 (5 mg/kg).
(E) Percentage protein binding of C21 in human and mouse plasma and mouse brain homogenate. Data shown represents the mean ± SEM of at
least three independent experiments.
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pERK1/2 levels. In all experiments, 10% FBS was used as a
positive control to measure the maximal levels of pERK1/2
stimulation. Time course experiments were ﬁrst performed to
determine the time at which the maximal pERK1/2 signal is
produced in response to each ligand (ACh at 100 μM and all
other ligands at 10 μM) over a 20 min period (0, 2, 5, 7, 10,
15, and 20 min) at 37 °C.
Concentration−response curves were generated by incuba-
tion of cells with increasing concentrations of each ligand for
5 min at 37 °C, as determined in the time course assays. Assays
were terminated by the removal of drugs and lysing the cells
with 50 μL/well SureFire lysis buﬀer (PerkinElmer Life Sci-
ences, Boston, MA). Following agitation for 10−15 min, 5 μL
of cell lysates were transferred into a 384-well white opaque
Proxiplate (PerkinElmer Life Sciences, Boston, MA), and incu-
bated with 8 μL of a mixture of reaction buﬀer, activation buﬀer,
acceptor beads, and donor beads in a ratio of 6:1:0.3:0.3 for
1.5 h in the dark at 37 °C. The signals were measured on an
EnVision plate reader (PerkinElmer Life Sciences, Boston, MA)
and normalized to the maximal response to ACh (for hM1 WT
or hM4 WT) or CNO (for hM1Dq or hM4Di).
Radioligand Binding Assays with Membranes. Radio-
ligand binding assays with membrane preparations to determine
binding aﬃnity were carried out as outlined before55 and by
the National Institute of Mental Health’s Psychoactive Drug
Screening Program (NIMH PDSP) (https://pdsp.unc.edu/),
Contract # HHSN-271−2013−00017-C. The NIMH PDSP is
Directed by B.L.R. at the University of North Carolina at
Chapel Hill, Chapel Hill, NC, and Project Oﬃcer Jamie
Driscoll at NIMH, Bethesda, MD.
Gi-Mediated cAMP Production (GloSensor cAMP)
Assays. HEK293 T cells were used for transient transfections
and Gi mediated cAMP production assays. Assays were per-
formed according to published procedures (PMID25895059,
PRESTO-Tango paper). More detailed assay protocols are
available at NIMH PDSP Web site (http://pdspdb.unc.edu/
pdspWeb/?site=assays).
Gq-Mediated Calcium Release (FLIPR) Assays. CHO
cells stably expressing human M3Dq receptors were used for
Gq-mediated calcium release assays. Assays were performed
according to published procedures (PMID25895059, PRES-
TO-Tango paper). More detailed assay protocols are available
Figure 8. C21 and CNO activates hM3Dq in neuronal cultures and in vivo. Recordings from lateral hypothalamic vGAT neurons infected
with AAV encoding either hM3Dq-mCherry or mCherry. Neurons were exposed to C21 (1 μM) in the presence of tetrodotoxin (TTX, 500 nM).
(A) Representative trace and (B) histogram on the right is the mean ± SEM with n = 6 cells for the hM3Dq and n = 3 cells for the mCherry
(* indicates p < 0.05, Student’s t test). (C−F) Food intake in animals in which hM3Dq or mCherry was virally induced to be expressed in
LH-vGAT neurons followed by administration of (C) C21 (0.3 mg/kg) (D) C21 (1.0 mg/kg), (E) C21 (3.0 mg/kg), and (F) CNO (3.0 mg/kg).
Data represents the mean ± SEM of 11 mCherry mice and 10 hM3Dq mice.
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at NIMH PDSP Web site (http://pdspdb.unc.edu/pdspWeb/
?site=assays).
GPCRome Screening (PRESTO-Tango) Assays. Poten-
tial agonist activity at human GPCRome was measured using
the PRESTO-Tango assay as published (PMID25895059,
PRESTO-Tango paper) with modiﬁcations. Brieﬂy, HTLA
cells were plated in 384-well white plates overnight and trans-
fected with receptor tango constructs (15 ng/well) for 24 h.
Transfected cells were then incubated with compounds in
DMEM supplemented with 1% dialyzed FBS for 18 h. Medium
and compound mixture were removed, and BrightGlo reagents
(Promega) were added to determine luciferase reporter activity.
The assay was designed so that each receptor construct had
4 replicate wells for testing drug and 4 replicate wells for
medium (vehicle) control. Results were represented in the
form of fold over average basal (vehicle control) for each recep-
tor. Dopamine receptor DRD2 is used as an assay control with
100 nM Quinpirole in each assay plate. Most receptors showed
activity from 0.5- to 2.0-fold of basal level. Follow-up assays are
usually not planned for observed activity with less than 3.0-fold
of basal level.
Gi1 BRET Dissociation Assay. Separate pcDNA plasmids
containing the sequence for Gβ1, Gγ2-GFP
2, Gi1-Rluc8, and
either human dopamine D2 receptor or histamine H4 receptor
were cotransfected into HEK293T cells (in 10 cm plates) at
1.5 μg/construct using Transit-2020 (Mirus) at a ratio of
3 μL/μg Transit/DNA. The next day, cells were harvested and
plated in DMEM containing 1% dFBS in polylysine-coated
96-well plates (Greiner) at 50 000 cells per well. Sixteen hours
later, media was aspirated from each well, and cells were
Figure 9. In vivo activation of hM3Dq expressed in ARCAgRP-neurons by C21 and CNO increases feeding behavior in sated mice. Light cycle food
intake was monitored following CNO or C21 administration at various concentrations to calorically replete AgRP-ires-CRE-expressing animals
infected with (A−C (n = 6)) AAV-DIO-hM3Dq-mCherry or (D−F (n = 6)) control non-CRE-expressing animals infected with AAV-DIO-hM3Dq-
mCherry. Data represents the mean ± SEM.
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subsequently rinsed with 60 μL of assay buﬀer (20 mM
HEPES, 1× Hanks Buﬀered Saline Solution, pH 7.4). Before
drug treatment, 60 μL of fresh assay buﬀer was added to each
well followed by 10 μL of 50 uM Coelenterazine 400a
(Prolume). Luminescence and ﬂuorescence were measured
using an LB940 Mithras (Berthold technologies), and BRET
was computed as the ratio of GFP2 ﬂuorescence to luciferase
signal.
cAMP Glo-sensor. HEK293T cells in 10 cm plates were
transfected with 4 μg of Glosensor and 4 μg of DNA encoding
the human dopamine D1 receptor. The next day, cells were har-
vested and plated in polylysine-coated 384-well plates (Greiner)
at a density of 20 000 cells/well in DMEM containing 1% dFBS.
The next day, media was aspirated from each well and replaced
with 20 μL of assay buﬀer containing 4 mM luciferin. Then,
10 μL of drugs were added 30 min later, and plates were read
after 15 min.
Data Analysis. All data were analyzed using GraphPad
Prism 7 (San Diego, CA). [3H]NMS inhibition binding data
were analyzed according to a one-site binding model,34 and the
equilibrium dissociation constants (Ki) of unlabeled ligands
were calculated using the Cheng and Prusoﬀ equation35 by con-
straining the radioligand Kd to the values estimated from satu-
ration binding assays. Concentration−response curves generated
from IP1 or pERK1/2 assays were ﬁtted to a three-parameter
logistic equation. All aﬃnity and potency values were estimated
as logarithms.36
Schild Analysis. For acetylcholine, dopamine or histamine
concentration response curves (Figures 2 and 3) in the pres-
ence of multiple concentrations of C21 the following form of
the Gaddum and Schild equations was applied globally to the
data sets:
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where “Top” represents the maximal asymptote of the curves,
“Bottom” represents the minimum asymptote of the curves,
log EC50 represents the logarithm of the agonist EC50 in the
absence of C21, [A] represents the concentration of agonist,
[B] represents the concentration of C21, nH represents the Hill
slope of the agonist curve, s represents the Schild slope for C21,
and pA2 represents the negative logarithm of the concentration
of C21 that shifts the agonist EC50 by a factor of 2. In the
absence of C21 ([B] = 0), this equation becomes the standard
four-parameter logistic equation for ﬁtting agonist concen-
tration−response data.
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